N/A
Completed N=59
Assessment of Airway Obstruction in Infants With Lower Respiratory Infections
Source: ClinicalTrials.gov NCT00435994 ↗Enrolled (actual)
59
Serious AEs
0.0%
Results posted
Jun 2016
Primary outcomePrimary: Lung Function — 0.071; -3.179; 0.186; -3.345 Z score — p=0.0020
Summary
The purpose of this study is to evaluate how two different aerosol medications may improve airway function in infants with respiratory illness. We are using two different medications and comparing the difference in lung function after each medication. We will also be taking a nasal wash sample for VEGF. We will be using this in comparing how infants respond to the aerosol medications as well. We hope to help standardize medications used for infants with bronchiolitis and RSV.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Lung Function |
0.071; -3.179; 0.186; -3.345; 0.041; -2.430 | 0.0020 sig |
| PRIMARY Endothelial Growth Factor (VEGF) |
183.526; 568.867 | .0020 sig |
Eligibility Criteria
Inclusion Criteria
- Group 1 Infants between 2 and 24 months that are healthy
- Group 2 Infants between 2 and 24 months that have RSV or bronchiolitis and defined as the first episode of wheezing
Exclusion Criteria
- Group 1 and 2 - no cardiac disease, no oxygen requirement, prematurity < 37 weeks, and cannot be in the ICU.
Data sourced from ClinicalTrials.gov (NCT00435994). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.